<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159810">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968694</url>
  </required_header>
  <id_info>
    <org_study_id>2010P002903</org_study_id>
    <nct_id>NCT01968694</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Lidocaine on Endometriosis Pain</brief_title>
  <official_title>Effects of Intravenous Lidocaine on Endometriosis Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this research study to find out if intravenous (in your vein, &quot;IV&quot;) lidocaine
      can lessen pain from endometriosis. The U.S. Food and Drug Administration (FDA) has approved
      intravenous lidocaine to treat irregular heart beats, but the FDA has not approved
      intravenous lidocaine to treat pain from endometriosis.  Intravenous lidocaine has been used
      for more than 25 years to treat different acute and chronic pain conditions but has not yet
      been studied for endometriosis pain.

      This is a cross-over trial over two months where one month you will receive the active
      medication (lidocaine) and one month you will receive the active placebo (diphenhydramine,
      commonly known as benadryl). We will compare the effect on pain from endometriosis of
      lidocaine to active placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Numeric Pain Score</measure>
    <time_frame>Two Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short Form McGill Pain Questionnaire 2</measure>
    <time_frame>Two Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
    <time_frame>Two Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>Two Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>IV Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes or normal saline 0.9% same volume given and infused over 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV diphenhydramine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes or normal saline 0.9% equal volume dosed as above.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Lidocaine</intervention_name>
    <arm_group_label>IV Lidocaine</arm_group_label>
    <arm_group_label>IV diphenhydramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV diphenhydramine</intervention_name>
    <arm_group_label>IV Lidocaine</arm_group_label>
    <arm_group_label>IV diphenhydramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Reproductive age women ages 18 - 50

          -  Endometriosis diagnosed laparoscopically or by primary care physician or
             gynecologist using clinical criteria

          -  Pain for &gt; 6 months

          -  Pain most intense around time of menstrual cycle. Pain at least 5 on a 0-10 scale.

          -  Receiving regular monthly menses (can be on hormonal therapy, excluding intrauterine
             devices or Depo-provera injections)

        Exclusion criteria:

          -  Pregnant or breastfeeding

          -  On lupron therapy

          -  History of myocardial infarction or cardiac arrhythmias including
             Wolff-Parkinson-White, severe sinoatrial, atrioventricular or intraventricular heart
             block in the absence of a pacemaker

          -  History of seizure disorder

          -  Significant anxiety, psychosis or other cognitive disorder limiting completion of
             study procedures

          -  History of alcohol or substance abuse

          -  Chronic pain symptoms other than chronic pelvic pain (excluding migraine pain)

          -  Known hypersensitivity to amide type anesthetics

          -  Known hypersensitivity to diphenhydramine (benadryl)

          -  History of treatment with lidocaine or mexilitene

          -  Having or showing signs and symptoms of liver disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antje Barreveld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Courtney Rust</last_name>
    <phone>617-732-9810</phone>
    <email>crust1@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Pain Management Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Rust</last_name>
      <phone>617-732-9810</phone>
      <email>crust1@partners.org</email>
    </contact>
    <investigator>
      <last_name>Antje Barreveld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 21, 2013</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Antje Barreveld, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>chronic pain</keyword>
  <keyword>intravenous lidocaine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
